Adjuvant Capecitabine/Gemcitabine for EHCC and GBCA
Melanie B. Thomas, MD, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.
Clinical Pearls
Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.
- Though surgery is the only curative option for patients with extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinomas (GBCA), there is still a high risk of the cancer returning.
- There remains a need for an option for these patients after surgery.
- This trial established the feasibility of adjuvant treatment in EHCC and GBCA.
More on this study > >
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
